10x Genomics director granted 8,829 RSUs

Teichmann Sarah A. reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Teichmann Sarah A. reported acquisition or exercise transactions in this Form 4 filing.

10x Genomics director Sarah A. Teichmann received an equity award of 8,829 restricted stock units (RSUs) of Class A Common Stock. The award was granted at no cash cost per share and increased her direct holdings to 35,609 shares.

Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. One quarter of the RSUs will vest on each quarterly anniversary starting from May 21, 2026, as long as she continues as a service provider through each vesting date.

Insider Trade Summary

Grant/Award: 8,829 shares

Grant/Award 1 txn

Insider Teichmann Sarah A.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	8,829	$0.00	$0.00

Holdings After Transaction: Class A Common Stock — 35,609 shares (Direct)

Footnotes (1)

1. F1. Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/4th of the RSUs shall vest on each quarterly anniversary measured from May 21, 2026, subject to the Reporting Person continuing as a service provider through each such date.

Key Figures

RSU grant size: 8,829 RSUs Post-grant holdings: 35,609 shares Grant price: $0.0000 per share +2 more

5 metrics

RSU grant size 8,829 RSUs Grant of Class A Common Stock RSUs to director

Post-grant holdings 35,609 shares Total Class A Common Stock directly held after transaction

Grant price $0.0000 per share RSUs awarded at no cash cost per share

Vesting start reference date May 21, 2026 Quarterly vesting anniversaries measured from this date

Vesting pattern 1/4 each quarter One quarter of RSUs vest on each quarterly anniversary

Key Terms

restricted stock units ("RSUs"), contingent right, service provider

3 terms

restricted stock units ("RSUs") financial

"Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right..."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

contingent right financial

"Each RSU represents a contingent right to receive one share of Class A Common Stock..."

service provider financial

"...subject to the Reporting Person continuing as a service provider through each such date."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did 10x Genomics (TXG) report for Sarah A. Teichmann?

10x Genomics reported that director Sarah A. Teichmann received a grant of 8,829 restricted stock units of Class A Common Stock. These RSUs are part of her equity compensation and convert into shares only as they vest over time.

How many 10x Genomics (TXG) shares does Sarah A. Teichmann hold after this Form 4?

After the equity award, Sarah A. Teichmann directly holds 35,609 shares of 10x Genomics Class A Common Stock. This total reflects the new 8,829-share RSU grant, which will settle into shares as vesting conditions are met over future dates.

Are the 8,829 RSUs for 10x Genomics (TXG) an open-market purchase or sale?

The 8,829 RSUs represent a grant, not an open-market purchase or sale. They are compensation-related restricted stock units awarded at no cash price, which will convert into Class A shares only as they vest according to the disclosed schedule.

What is the vesting schedule for Sarah A. Teichmann’s 8,829 RSUs in 10x Genomics (TXG)?

The 8,829 RSUs vest in four equal installments. One quarter of the RSUs will vest on each quarterly anniversary measured from May 21, 2026, provided Sarah A. Teichmann continues as a service provider through each corresponding vesting date.

What does each RSU granted to Sarah A. Teichmann by 10x Genomics (TXG) represent?

Each RSU represents a contingent right to receive one share of 10x Genomics Class A Common Stock. She receives actual shares only when RSUs vest, assuming she continues her service, aligning part of her compensation with long-term shareholder interests.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/08/2026 - 07:27 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Teichmann Sarah A.

(Last) (First) (Middle)

C/O 10X GENOMICS, INC.

6230 STONERIDGE MALL ROAD

(Street)

PLEASANTON CALIFORNIA 94588

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
10x Genomics, Inc. [ TXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	06/04/2026		A		8,829(1)	A	$0	35,609	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/4th of the RSUs shall vest on each quarterly anniversary measured from May 21, 2026, subject to the Reporting Person continuing as a service provider through each such date.

	/s/ Randy Wu, as Attorney-in-Fact for Sarah A. Teichmann	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)